SCHEMBL6934249

SCHEMBL6934249

CCCCCNc1nc(-c2ccncc2)c(-c2ccc(F)cc2)c(=O)n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.46
MAPK13 O15264 5/20 0.46
MAPK12 P53778 4/20 0.46
MAPK9 P45984 3/20 0.46
MAP4K4 O95819 2/20 0.46
CSNK1D P48730 2/20 0.46
CDC42BPA Q5VT25 2/20 0.46
MINK1 Q8N4C8 2/20 0.46
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
LYN P07948 1/20 0.46
PRKACA P17612 1/20 0.46
PRKCI P41743 1/20 0.46
MAPK8 P45983 1/20 0.46
MAPK10 P53779 1/20 0.46
MAP3K10 Q02779 1/20 0.46
PRKCZ Q05513 1/20 0.46
PRKCD Q05655 1/20 0.46
CAMK2B Q13554 1/20 0.46
CAMK2G Q13555 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6932796 0.97 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6934712 0.87 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6929508 0.87 CYP3A4 (0.55) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6933043 0.86 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6931494 0.86 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK9MAP4K4
Butylamine SCHEMBL6931853 0.85 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6934372 0.85 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6932108 0.85 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK9MAP4K4
SCHEMBL6932167 0.85 QPCT (0.54) MAPK14MAPK13MAPK12MAPK9MAP4K4
Butylamine SCHEMBL6933493 0.85 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK9MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A MAPK14 1169/4885MAPK13 1577/4885MAPK12 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.